This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
II-VI (IIVI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
II-VI's (IIVI) Q2 earnings are likely to have gained from the solid product demand, the Finisar buyout and strong sales channels. However, high costs and expenses might have marred its performance.
Parker-Hannifin (PH) to Post Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strength in life science, semiconductor, rail and power end markets is expected to have boosted Parker-Hannifin's (PH) fiscal Q2 earnings. Soft automotive and oil and gas space might have been drags.
Emerson (EMR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Emerson's (EMR) Q1 earnings are likely to have gained from solid medical, life science, & power end markets. Weak process & discrete end markets, and coronavirus-led woes might have played spoilsport.
Fortune Brands (FBHS) to Post Q4 Earnings: Beat in Store?
by Zacks Equity Research
Solid demand for decking products and strength in security business and plumbing businesses are expected to have aided Fortune Brands' (FBHS) Q4 earnings. High costs might have been a spoilsport.
Options Traders Expect Huge Moves in Axovant (AXON) Stock
by Zacks Equity Research
Investors need to pay close attention to Axovant (AXON) stock based on the movements in the options market lately.
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
by Zacks Equity Research
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
by Zacks Equity Research
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
by Zacks Equity Research
Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
by Zacks Equity Research
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
Novartis Gets Approval for Gene Therapy Luxturna in Europe
by Zacks Equity Research
Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.
Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axovant Sciences (AXON) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
by Zacks Equity Research
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.
Top Ranked Momentum Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:
Implied Volatility Surging for Axovant (AXON) Stock Options
by Zacks Equity Research
Axovant (AXON) needs investors to pay close attention to the stock based on moves in the options market lately.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
by Zacks Equity Research
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.